DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

Trial status:Will Be Recruiting
Trial ID:
DB-1311-201
NCT ID:
NCT06953089
EudraCT ID:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
DualityBio Inc.
Will Be Recruiting

Trial Details

A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors

Medical Condition
  • Solid Tumors
    • Trial Drug
  • DB-1311/BNT324
    • See more
  • BNT327
  • DB-1305/BNT325
    • Phase
    Phase 2
    Type
    Interventional
    Estimated Enrolment
    440
    Estimated Trial Date
    Jun 2025 - Jun 2030

    Trial Participant Requirements

    Age
    18+ years
    Sex
    Female & Male
    Healthy Volunteers
    No

    Trial Locations

    Location
    Status
    Location
    Research Site USA04-0
    New York, New York, United States, 10032
    Status
    Location
    Research Site USA03-0
    Charleston, South Carolina, United States, 29425
    Status
    Location
    Research Site AUS02-0
    North Ryde BC, New South Wales, Australia, 2109
    Status
    Location
    Research Site CHN09-0
    Hefei, Anhui, China, 230022
    Status
    Location
    Research Site CHN02-0
    Beijing, Beijing, China, 100021
    Status
    Location
    Research Site CHN03-0
    Beijing, Beijing, China, 100142
    Status